First Tracks Biotherapeutics Shares Surge 6.91% on Positive Phase 1b Celiac Disease Data

Key highlights

• Phase 1b Cohort 1 trial for ANB033 met positive topline objectives in Celiac Disease patients
• Company shares rose 6.91% to $34.05 following the clinical update on October 12, 2026
• Projected cash runway remains sufficient to fund operations through the second quarter of 2028
• Cohort 2 data for the Celiac Disease trial is scheduled for release in the first quarter of 2027
• Clinical expansion into eosinophilic esophagitis is underway with data expected in Q3 2027

What Happened

First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX) disclosed positive topline results from the initial cohort of its Phase 1b clinical trial evaluating ANB033. The study focuses on patients with Celiac Disease, an autoimmune disorder triggered by gluten consumption. In addition to the clinical update, the company refreshed its corporate investor presentation to reflect these results and updated its development roadmap. The market reacted favorably to the news, with the stock price climbing 6.91% to $34.05 during the trading session on October 12, 2026. This announcement follows the company's emergence as an independent entity earlier this year.

Down 7.0% since our story on 13 Oct: $34.05 when we broke it → $31.68 at the close on 13 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$37.57
15 Sep	$38.47
16 Sep	$39.00
17 Sep	$39.20
18 Sep	$38.60
21 Sep	$38.99
22 Sep	$41.03
23 Sep	$36.66
24 Sep	$35.83
25 Sep	$34.42
28 Sep	$36.65
29 Sep	$35.98
30 Sep	$35.44
1 Oct	$33.92
2 Oct	$33.28
5 Oct	$32.99
6 Oct	$31.39
7 Oct	$30.59
8 Oct	$32.01
9 Oct	$31.85
12 Oct	$34.05
13 Oct	$31.68

Significance

• Validation of the ANB033 mechanism of action within the specific Celiac Disease patient population
• Clearance for the progression of the clinical pipeline into second-cohort evaluations
• Reiteration of a multi-year cash runway extending into mid-2028 to support R&D
• Upcoming catalysts include additional Celiac data in early 2027 and EoE data later that year

Business Overview

Headquartered in San Diego, First Tracks Biotherapeutics is a clinical-stage biotechnology firm specializing in the development of therapies for inflammatory and autoimmune conditions. The company completed its spin-off from AnaptysBio in April 2026, coinciding with a $145 million private placement financing and its debut on the Nasdaq Global Market. Its lead candidate, ANB033, is being studied for multiple indications, including Celiac Disease and eosinophilic esophagitis. By targeting specific immune pathways, the company aims to address unmet needs in gastroenterology where limited pharmacological options currently exist for patients managing strict dietary restrictions.

Financial Context

As a clinical-stage entity, First Tracks does not currently generate revenue from product sales and reported no order backlog as of June 30, 2026. The company’s market capitalization stands at approximately $1.22 billion. Despite a month-over-month price decline of 10.35%, the recent clinical data helped stabilize the technical outlook, with the Relative Strength Index currently at 44.3. Financial stability is anchored by the proceeds from its April debut, providing sufficient capital for operations through the next six quarters of planned clinical milestones, including Phase 1b expansions and secondary indication readouts.

Industry Landscape

• The Celiac Disease market is characterized by high unmet demand for non-dietary therapies
• Biotechnology firms in the autoimmune sector face high R&D costs and rigorous trial requirements
• Strategic spin-offs from larger biopharma entities like AnaptysBio are increasingly common to unlock value
• Investor sentiment in small-cap biotech remains sensitive to early-stage clinical trial data readouts

First Tracks Biotherapeutics, Inc. · financial snapshot

Share price	$34.05
Market cap	$1.2B
1-month price change	-10.35%
Sector	HealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.